Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Fluorescent boron-cluster dyes as biocompatible photosensitizers with promising antimicrobial and anticarcinogenic activity

Project description

Photosensitisers for antimicrobial photodynamic therapy efforts

The increasing resistance of microorganisms such as bacteria, fungi, and viruses to antimicrobials and antiseptics poses a serious threat to medicine and biology. This growing issue leads to rising infection rates and approximately 20 000 deaths annually due to multidrug-resistant bacteria, making it a critical public health challenge. Supported by the Marie Skłodowska-Curie Actions programme, the JAVIEROH project will develop innovative boron-rich biocompatible photosensitisers with suppressed π-π interactions and enhanced O2 production. These photosensitisers will serve as antimicrobial photodynamic therapy (aPDT) agents and antitumour agents for cancer treatments, contributing to efforts to combat this pressing global health threat.

Objective

The increasing resistance of microorganisms (bacteria, virus, fungi...) against antimicrobials and antiseptics is one of the most challenging topics in current medicine and biology. Statistics from the Centre for Disease Control and Prevention suggest that bacterial resistance to antibiotics causes over 20.000 deaths every year in EU member states alone. The European Centre for Disease Prevention and Control (ECDC) alerts that healthcare-associated infections caused mainly by multidrug-resistant (MDR) bacteria remain a public health issue and emphasizes the importance and urgency to search for effective alternative approaches based on completely different mechanisms. One of the promising approaches to fight against infections is the antimicrobial photodynamic therapy (aPDT) using biocompatible photosensitizers.
Compared to classical antimicrobials, the biggest advantage of aPDT is the very low probability that the target microorganisms have the opportunity to develop resistance. Furthermore, aPDT can be synergistically combined with other antibacterial treatments, such as radiotherapy, antibiotic treatments, and photothemal therapy, to improve its antibacterial efficiency. The main goal of this project is to engineer novel boron rich biocompatible photosensitizers, with suppressed π-π interactions and herewith enhanced for efficient singlete O2 production, to be used in a twofold objective: a) as aPDT agents for the inactivation of microorganisms in sanitary instruments and medical devices; b) as antitumor agents in dual PDT-BNCT cancer therapies. The innovation is focused on the development boron content PSs with multiple applications both for antimicrobial (aPDT) and anti-cancer (PDT and BNCT)

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2022-PF-01

See all projects funded under this call

Coordinator

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Net EU contribution
€ 165 312,96
Address
CALLE SERRANO 117
28006 Madrid
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
No data

Partners (1)